Dopavision Appoints Dr. Dirk Sauer as Chair of the Company’s Advisory Board

– Former Head of Novartis’ Ophthalmology Development Unit to provide significant product development expertise and industry network Berlin, Germany, November 16, 2022 — Dopavision, a clinical-stage company pioneering the development of digital therapeutics, today announced the appointment of Dr. Dirk Sauer as Chairman of the Company’s Advisory Board. Dirk Sauer brings an exceptional track record […]

Printable Resources

PRINTABLE RESOURCES Return to Portal Home Downloadable Resource Welcome letter Storyboard EN DOCPPT DE DOCPPT ES DOCPDF PT DOCPDF NL DOCPDF Daily schedule Activity cards Weekly schedule (1) Weekly schedule (2) Monthly schedule PDFPDFPDFPDFPDF PDFPDFPDFPDFPDF PDFPDFPDFPDFPDF PDFPDFPDFPDFPDF PDFPDFPDFPDFPDF Goal chart (1) Goal chart (2) PDFPDF PDFPDF PDFPDF PDFPDF PDFPDF At-home reward system Clinic reward system […]

Dopavision Appoints Mark S. Wuttke, Ph.D., as Chief Executive Officer

– Former Novartis ophthalmology program head significantly strengthens Dopavision’s management capabilities – Company recently initiated clinical trial of novel digital therapeutic for childhood myopia Berlin, Germany, May 25, 2022 — Dopavision, a company pioneering the development of digital therapeutics, today announced that Mark S. Wuttke, Ph.D., has been appointed as the Company’s Chief Executive Officer. […]


FREQUENTLY ASKED QUESTIONS Technical FAQs Trial FAQs Return to Portal Home Technical FAQs Download all FAQs as a PDF This section provides guidance on how to respond to some common technical concerns with which caregivers may reach out to you. If you do not feel confident helping a caregiver with a technical question, please assure […]

Report a Technical Issue

REPORT A TECHNICAL ISSUE Technical Issue Form Return to Portal Home We encourage you to use this form to report technical issues you or participants may be experiencing. The information provided in this form goes directly to our Product team at Dopavision. One of our technical experts will review the report and get in touch […]


Tips How to Navigate Technical Issues How to Report Technical Issues Return to Portal Home Navigating Technical Issues Download as a PDF Dopavision does its best to ensure that the MyopiaX and content apps have no technical issues. Yet, unforeseen technical issues may still occur during the MyopiaX-1 clinical trial. If a participant’s caregiver reports […]


GUIDES Weekly Low Adherence Calls Return to Portal Home Purpose: Understand why children have not been performing the recommended number of treatment sessions over the past week. Download as a PDF Goal: Motivate participating children and their caregivers to resume the twice daily treatment sessions as soon as possible by: Building rapport… inquire about how […]

Ensaio clínico

ENSAIO CLÍNICO DE QUE TRATA O ENSAIO CLÍNICO MYOPIAX®? A finalidade deste ensaio é investigar a eficácia de MyopiaX® MyopiaX® é uma aplicação para smartphone destinada a abrandar o avanço da miopia em crianças e adolescentes. Estamos a levar a cabo um ensaio clínico (NCT04967287) para investigar a segurança e a eficácia de MyopiaX® para controlar o […]

Klinisch onderzoek

KLINISCH ONDERZOEK WAAR GAAT HET KLINISCH MYOPIAX®-ONDERZOEK OVER? Het doel van dit onderzoek is het bestuderen van de werkzaamheid van MyopiaX® MyopiaX® is een smartphone-applicatie waarmee een behandeling wordt gegeven om de progressie van myopie bij kinderen en adolescenten te vertragen. We voeren een klinisch onderzoek uit (NCT04967287) naar de veiligheid en werkzaamheid van MyopiaX® om de […]

Klinische Studie

KLINISCHE STUDIE WORUM GEHT ES BEI DER KLINISCHEN MYOPIAX®-STUDIE? In dieser Studie soll die Wirksamkeit von MyopiaX® untersucht werden MyopiaX® ist eine Smartphone-Anwendung, die eine Behandlung zur Verlangsamung des Fortschreitens der Myopie bei Kindern und Jugendlichen bietet. Wir führen eine klinische Studie (NCT04967287) durch, um die Sicherheit und Wirksamkeit von MyopiaX® zur Kontrolle des Fortschreitens der Myopie […]